Clinical trial · no report yet · Phase 3
THOR
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
- NCT03390504 ↗
- Active, not recruiting
- Janssen Research & Development, LLC
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 107 | |
| Podcasts | 48 | |
| YouTube | 36 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Urothelial Cancer
- Interventions
- Erdafitinib; Vinflunine; Docetaxel; Pembrolizumab; Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
- Arms
- Cohort 1 (Arm 1A): Erdafitinib · Experimental
- Cohort 1 (Arm 1B): Vinflunine or Docetaxel · Experimental
- Cohort 2 (Arm 2A): Erdafitinib · Experimental
- Cohort 2 (Arm 2B): Pembrolizumab · Experimental
- Enrollment
- 629
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Mar 23, 2018
- Primary completion
- Apr 15, 2024
- Results posted
- Yes
- Registry record
- NCT03390504 · updated Sep 25, 2026
Publications
linked from the registry- Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. PubMed 37870920